What type of study is this?

This is a Cohort Study study (also classified as: Human Clinical Trial).

What question did this study set out to answer?

This research aims to assess real-world outcomes of elotuzumab in patients with relapsed/refractory multiple myeloma after lenalidomide maintenance therapy.

December 8, 2025Blood

Real-world outcomes with elotuzumab, lenalidomide, and dexamethasone in patients progressing on lenalidomide maintenance therapy: A single-center retrospective analysis

View Full Paper

Ask AI

Bookmark

Authors

SPSarah ParkerCedars-Sinai Smidt Heart Institute HBH BattagliaRoswell Park Comprehensive Cancer Center JHJens HillengassRoswell Park Comprehensive Cancer Center

Discussion

Member takes

Implication

Retrospective analysis reveals modest outcomes with EloRD in relapsed/refractory multiple myeloma, suggesting ongoing clinical relevance.

Key Points

This research aims to assess real-world outcomes of elotuzumab in patients with relapsed/refractory multiple myeloma after lenalidomide maintenance therapy.
Conducted a single-center retrospective analysis
Included adult patients with relapsed/refractory multiple myeloma
Estimated overall response rate and overall survival using the Kaplan–Meier method
Performed risk stratification based on IMS-IMWG Consensus Genomic Staging
Median overall survival from elotuzumab initiation was 73.9 months
79% of patients discontinued elotuzumab treatment, primarily due to progressive disease
Compared to ELOQUENT-2, observed a lower overall response rate but longer overall survival

Cite This Study

Parker et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4ed https://doi.org/10.1182/blood-2025-7532

View Full Paper

Ask AI

Bookmark

Real-world outcomes with elotuzumab, lenalidomide, and dexamethasone in patients progressing on lenalidomide maintenance therapy: A single-center retrospective analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world outcomes with elotuzumab, lenalidomide, and dexamethasone in patients progressing on lenalidomide maintenance therapy: A single-center retrospective analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider